Loading...

ONCOTELIC THERAPEUTICS INC Contract Awards 8-K Filing

NCTL

ONCOTELIC THERAPEUTICS INC

()

2025 8-K

Joint Development Agreement

Product Launch Announcement

Research Presentation

Financing Agreement

Stock Agreement Details

Milestone Amendment

Contract Amendment

Funding Agreement Completed

Debt Financing Agreement

Access to Research Tools

Investment Offering Details

Investor Presentation Update

Equity Offerings

Presentation Announcement

External Links:

On March 23, 2025, Oncotelic Therapeutics' CEO Dr. Vuong Trieu presented at a cancer symposium, and on March 25, 2025, the company announced successful Phase 1 trial results for OT-101 and IL-2.

AI Assistant

ONCOTELIC THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.